WeVote
Log In

Bill

Bill

HB 115

HEALTH SERVICES: Provides relative to the donation of source plasma

2025 Regular Session Introduced by Joe Stagni

Louisiana law now regulates source plasma donation standards, facilities, and donor requirements effective August 1, 2025, affecting blood supply and therapeutic medication availability.

Signed by the Governor. Becomes Act No. 60.
0
WeVote Research Nonpartisan
Bill Summary · HB 115

Legislative bill overview

HB 115 amends Louisiana law to regulate the donation and collection of source plasma (the liquid component of blood used for therapeutic products). The bill, now Act No. 60, establishes or modifies requirements for plasma donation facilities, donor eligibility, and related health and safety standards effective August 1, 2025.

Why is this important

Source plasma is a critical raw material for manufacturing life-saving medications, including immunoglobulins and clotting factors. Changes to donation regulations directly affect the blood supply chain, donor compensation policies, and public health infrastructure—impacting both patients dependent on plasma-derived therapies and individuals who donate plasma for income.

Potential points of contention

  • Donor compensation limits: The bill may impose restrictions on how much donors can be paid, raising concerns from the plasma industry (which relies on paid donors) versus public health advocates worried about coercive practices targeting low-income individuals
  • Facility operational standards: New regulatory requirements could increase compliance costs for collection centers, potentially reducing the number of facilities or affecting donation accessibility in rural areas
  • Donor health protections vs. supply needs: Stricter eligibility criteria or screening protocols might improve safety but could reduce the available donor pool at a time when plasma demand for therapeutic treatments continues growing

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.